An international, randomized, double-blind, placebo-controlled, study of valacyclovir for the suppression of herpes simplex virus type 2 genital herpes in newly diagnosed patients

摘要: BACKGROUND: Antiviral suppressive therapy of genital herpes is often initiated based on the established pattern recurrences in an individual. Because most persons with first episode simplex virus type 2 (HSV-2) infection experience and because viral shedding occurs frequently year after we examined strategy initiating shortly diagnosis HSV-2 infection. SUBJECTS AND METHODS: From June 16 2004 to July 26 2006 384 subjects from 74 sites United States Canada Argentina Brazil Chile who were newly diagnosed a recognized at time screening visit or within 3 months before randomized (2:1) receive valacyclovir 1 g once daily placebo for 24 weeks. Subjects instructed return clinic during suspected outbreaks clinician confirmation recurrences. RESULTS: Valacyclovir significantly prolonged recurrence compared approximately 43% 71% recurrence-free weeks (P <0.001). reduced mean number per month occurring 24-week study period (0.11 0.48 P Adverse events comparable arms. CONCLUSION: administered was well-tolerated effective suppressing immunocompetent without pattern.